Actelion to buy Ceptaris, as long as FDA OKs Valchlor
This article was originally published in Scrip
Executive Summary
The Swiss company Actelion is to buy the privately owned Ceptaris, but only if the US FDA approves Ceptaris' Valchlor, which would become the first authorized topical mechlorethamine gel for treating early stage mycosis fungoides-type cutaneous T cell lymphoma (CTCL).